Health TrialsbyHealthPanel

Influence of Cardiopulmonary Rehabilitation on Cardiorespiratory Adaptation in Patients With Pulmonary Hypertension

ConditionPulmonary Hypertension Due to Lung Disease (Disorder)
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age45-65
SponsorCairo University

About this trial

This study aims to investigate the effect of cardiopulmonary rehabilitation on cardiorespiratory parameters and functional capacity in patients with pulmonary hypertension.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

g)Uncontrolled systemic HTN. h)Other types of pulmonary hypertension.. i)Smoker j)Any condition of kidney failure. k)Neurological or musculoskeletal conditions that interfere with gait

Trial design

Design model

Parallel

Treatments tested in this trial

  • cardiopulmonary rehabilitation in the form of moderate-intensity interval aerobic training

    Behavioral

    Training will be conducted on a treadmill three times weekly for 12 weeks. Exercise intensity will progress from 30-40% to 60-70% of target heart rate. Each session will last 30 minutes and include warm-up and cool-down periods.

  • Inspiratory Muscle Training

    Device

    inspiratory muscle training will be performed using a Threshold Inspiratory Muscle Trainer (Philips Respironics). Training intensity will correspond to moderate-to-severe effort (3-5 on the Modified Borg Scale).

  • Medical treatment

    Other intervention

    medication

Treatment groups

42 Participants
are divided into 4 treatment groups
Group A: group III PH with obstructive lung diseaseExperimental treatment 2 interventions
Group B: group III PHT with restrictive lung diseaseExperimental treatment 2 interventions
Group C: control group III PH with obstructive lung diseaseExperimental treatment 1 intervention
Group D: control group III PHT with restrictive lung diseaseExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

6-minute walk distance

total distance walked in 6 minutes

Time frame
12 weeks
2

Maximal Oxygen Consumption

Estimated VO2max

Time frame
12weeks
3

spirometry

FEV1, FVC, FEV1/FVC, MVV

Time frame
12weeks

Secondary outcomes

1

Dyspnea Severity

Modified Borg Scale

Time frame
12weeks
2

change Pulmonary Artery Pressure

pulmonary artery pressure estimated by ECHO

Time frame
12weeks
3

change of total score of SF-12 Questionnaire) Quality of Life

more increase scores more increase quality of life

Time frame
12weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Cairo University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: